{"title":"Apixaban vs. Warfarin in Patients with Thrombotic Antiphospholipid Antibody Syndrome","authors":"B. Stein, Mhs","doi":"10.1056/NEJM-JW.NA54241","DOIUrl":null,"url":null,"abstract":"Direct oral anticoagulants (DOACs) have replaced warfarin as the anticoagulant of choice in most clinical situations. However, warfarin has remained as","PeriodicalId":19048,"journal":{"name":"NEJM Journal Watch","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NEJM Journal Watch","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1056/NEJM-JW.NA54241","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Direct oral anticoagulants (DOACs) have replaced warfarin as the anticoagulant of choice in most clinical situations. However, warfarin has remained as
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
